Gene Therapy Market Research Report: By Type (In vivo, Ex vivo), Vector Type (Viral, Non-Viral), Application (Oncology, Rare Diseases, Neurology, Ophthalmology, Hematology, Infectious Diseases, Cardiology), End User (Pharmaceutical and Biotechnology Companies, Academic Institutes and Research Centers) - Global Industry Outlook and Growth Forecast to 2030

  • Published: January 2020
  • Report Code: LS11991
  • Available Format: PDF
  • Pages: 198

Market Outlook

The gene therapy market revenue stood at $3,407.5 million in 2019, and the market is predicted to progress at a CAGR of 31.1% between 2020 and 2030. The increasing prevalence of chronic diseases, surging number of research and development (R&D) projects in this field, and positive results of the recently conducted clinical trials across the world are the major factors driving the growth of the market.

Gene Therapy Market Outlook

Segmentation Analysis of Gene Therapy Market

The in vivo category is predicted to lead the market for gene therapy in the coming years, under the type segment. This will be because this method eliminates the requirement for removing the cells from the patient’s body, manipulating them outside the body, and then returning them to their original place. Additionally, unlike the ex vivo method, it causes no harm to the host cells and, thus, does not disrupt their functioning.

In the forthcoming years, the viral category is predicted to exhibit the fastest growth in the market for gene therapy, under segmentation by vector type. This will be due to the fact that viral vectors are exhibiting high levels of genomic expression and incorporation in clinical trials. Moreover, viral vectors are more efficient than non-viral variants and are, thus, widely being adopted all over the world.

The oncology category generated the highest revenue in the gene therapy market in 2019, under the application segment. This is credited to the high incidence of cancer and the fact that around 60% of the currently ongoing clinical trials in the field of gene therapy are aimed at cancer treatment, because gene therapy is high selective in killing tumor cells.

Pharmaceutical and biotechnology companies contributed the highest revenue to the market from 2014 to 2019, under segmentation by end user. This was due to the existence of several industry players who outsourced the vector production process for expanding the application of gene therapy, so that it can be applied to many more diseases than presently.

North America held the largest share in the market in 2019, and this trend is expected to continue in the forthcoming years. This is ascribed to the increasing prevalence of rare diseases and cancer and presence of several leading industry players in the region. In addition, regulatory authorities in the region are rapidly approving gene therapy products, thereby fueling the expansion of the market.

Gene Therapy Market Regional Analysis

Outsourcing of Manufacturing of Gene Therapy Products Major Market Trend

One of the major trends currently being witnessed in the gene therapy market is the outsourcing of the manufacturing of gene therapy products by the leading industry players. They are outsourcing the production to contract manufacturing organizations (CMO) in order to improve their operational efficiency and productivity and attain reduced time-to-market and quality gains.

For example, Prevail Therapeutics Inc., which produces gene therapy products based on the adeno-associated-virus (AAV) for patients diagnosed with neurodegenerative diseases, announced in October 2019 that it has signed an agreement with Lonza for developing products that comply with good manufacturing practices (GMP). As per the agreement, Lonza will develop Prevail’s PR006 and PR001 gene therapies.

Gene Therapy Market Growth Drivers

Rising Incidence of Chronic Diseases Fueling Market Expansion

The growing prevalence of chronic diseases, such as cancer and various rare diseases, is one of the major factors driving the progress of the market. The reason behind this is that the currently available gene therapies can treat various rare diseases, especially those that are caused due to genetic problems, to some extent. For example, cancer-targeting therapies do not generate a demand for long-term transgene expression.

According to the American Cancer Society, in the U.S., the number of new cancer cases grew from 1,685,210 to 1,762,450 from 2016 to 2019. Similarly, the country witnessed a massive rise in cancer mortality, from 595,690 to 606,880 from 2016 to 2019. Issues such as this have propelled the expansion of the gene therapy market in the country and the world.

Advancements in Production Processes Creating Immense Growth Opportunities

The growth of the gene therapy industry is being slightly hampered by the low production volume, high production costs, high capital requirements, and long lead times. To overcome these issues, the automation of the production process is becoming necessary, as this will drastically reduce the requirement for manual labor, variability in production, and the cost of the products. Additionally, the manufacturing and throughput efficiency can be augmented without affecting the purity of the active particles by enhancing the vector and cell technologies. Moreover, the optimization of therapy delivery systems would reduce the need for invasive intrathecal and intracellular injections and improve the management of blood, liver, immune system, eye, and spine diseases.

Gene Therapy Market Report Coverage
Report Attribute Details
Historical Years 2014-2019
Forecast Years 2020-2030
Market Size by Segments Type, Vector Type, Application, End User
Market Size of Geographies U.S., Canada, Germany, France, Italy, Spain, U.K., Japan, China, India, South Korea, Brazil, Mexico, Saudi Arabia, South Africa
Market Players Spark Therapeutics Inc., bluebird bio Inc., Orchard Therapeutics plc, Amgen Inc., REGENXBIO Inc., Thermo Fisher Scientific Inc., Applied Genetic Technologies Corporation, Pfizer Inc., Adverum Biotechnologies Inc., Novartis AG


Market Players Engaging in Collaborations and Partnerships for Enhanced Growth Prospects

In recent years, the gene therapy market players have engaged in a number of collaborations and partnerships, to leverage each other’s expertise and technologies for mutual business prosperity.

For instance, Forty Seven Inc. and bluebird bio Inc. began a research collaboration in November 2019, for pursuing proof-of-concept clinical trials for Forty Seven Inc. Under the terms, the latter firm’s FSI-174 (anti-cKIT antibody) plus magrolimab (anti-CD47 antibody), which is a antibody-based conditioning regimen, will be tested together with lentiviral vector hematopoietic stem cell (LVV HSC), an ex vivo gene therapy platform developed by bluebird. The collaboration, aimed at a conditioning approach which would reduce toxicity, will be initially targeted at diseases that can be managed by transplanting autologous gene-modified blood-forming stem cells.

In the same vein, in August 2019, NIBRT and Allergan plc began a partnership to develop AAV-based gene therapies. The partnership focuses on establishing transfection/transduction conditions to minimize incorrect packaging events, optimizing the cell culture process of infectious AAV particles of various serotypes, and investigating sensitive analytical methods to differentiate between full and empty plastids.

The major players in the global gene therapy market are Spark Therapeutics Inc., bluebird bio Inc., Orchard Therapeutics plc, Amgen Inc., REGENXBIO Inc., Thermo Fisher Scientific Inc., Applied Genetic Technologies Corporation, Pfizer Inc., Adverum Biotechnologies Inc., and Novartis AG.

Market Size Breakdown by Segment

The gene therapy market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.

Based on Type

  • In vivo
  • Ex vivo

Based on Vector Type

  • Viral
    • Adeno-associated virus (AAV)
    • Adenovirus
    • Lentivirus
    • Retrovirus
  • Non-Viral

Based on Application

  • Oncology
  • Rare Diseases
  • Neurology
  • Ophthalmology
  • Hematology
  • Infectious Diseases
  • Cardiology

Based on End User

  • Pharmaceutical and Biotechnology Companies
  • Academic Institutes and Research Centers

Geographical Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
  • Asia-Pacific
    • Japan
    • China
    • India
    • South Korea
  • Latin America
    • Brazil
    • Mexico
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
Frequently Asked Questions About This Report
How much value did the gene therapy market attain in 2019?+
What is the expected CAGR in the gene therapy industry between 2020 and 2030?+
Which region will register the fastest growth in the gene therapy market in the future?+
What are gene therapy industry players doing these days?+
What are the main segments of the gene therapy market?+
Place An Order
USD 4900 USD 5900 USD 7500
Customized Report Solution

Get a bespoke market intelligence solution

We are committed to ensuring the highest level of client satisfaction
Quality Acknowledgement
Quality Acknowledgement

Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you

Unmatched Standards
Unmatched Standards

Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights

Reach Us
Reach Us Whenever You Need Us

With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required

Data Security
Complete Data Security

We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws